Table 2.
Equine influenza vaccine breakdown observed in horses with up to date vaccination records.
| Last Vaccine Dose (Manufacturer) | No. of Horses (%) | Vaccine Breakdown (%) | No. of Days Since V2 | No. of Days Since V3 or Subsequent Booster | Representative H3N8 American Lineage Vaccine Strain |
|---|---|---|---|---|---|
| Duvaxyn IET Plus (Elanco Animal Health) |
43 (44%) |
13/43 (30%) |
124 (n = 1) |
276 ± 27.7 SE (n = 12) |
A/eq/Newmarket/1/93 |
| Equip FT (Zoetis) |
10 (10%) |
5/10 (50%) |
189 (n = 1) |
267 ± 51.2 SE (n = 4) |
A/eq/Kentucky/98 |
| Equilis Prequenza Te (MSD Animal Health) |
32 (33%) |
9/32 (28%) |
135 ± 33.5 SE (n = 2) |
217 ± 35.7 SE (n = 7) |
A/eq/South Africa/4/03 1 |
| ProteqFlu Te (Merial) |
13 (13%) |
3/13 (23%) |
42 (n = 1) |
257 ± 95.5 SE (n = 2) |
A/eq/Ohio/03 2 |
| Total/average | 98 | 30/98 (31%) |
125 ± 25.9 SE (n = 5) |
261 ± 19.6 SE (n = 25) |
No. = number; No. of days since V2 = the number of days since the horse received the second dose of the primary vaccination. No. of days since V3 = the number of days since the horse received the third dose of the primary vaccination. 1 Equilis Prequenza updated vaccine became available in Ireland in 2013 and includes Clade 1 Florida sublineage of the American lineage (FCL1) representative vaccine strain A/eq/South Africa/4/03 (previously contained A/eq/Newmarket/1/93). 2 ProteqFlu updated vaccine became available in Ireland in December 2014 and includes recombinant canarypox viruses expressing the haemagglutinin gene of A/eq/Ohio/03 (FCL1) and A/eq/Richmond/1/07 (FCL 2).